Helena H. Chaye

Western Oncolytics Ltd. develops novel therapies for cancer. The private company is based in Westlake. Helena H. Chaye has been the CEO of the American company since 2019.

Kalivir Immunotherapeutics, Inc. is a privately held biotech company based in Pittsburgh, PA. The company is focused on developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs. Kalivir has developed a unique virus-based platform, enhanced template "vet" platform, that can generate potent novel oncolytic viruses with modifications to maximize viral replication and to enhance intravenous delivery and spread. The company has separate collaborations with Roche and Astellas Pharma to design and generate novel oncolytic viruses derived from the vet™ platform. Kalivir is currently advancing multiple therapeutic candidates toward the clinic. The CEO of the company is Helena H. Chaye.

SillaJen Biotherapeutics, Inc. develops and commercializes cancer therapeutics. It focuses on the development and commercialization of first-in-class, breakthrough targeted oncolytic immunotherapy products for solid tumors. It is focused on two main programs, lead product candidate, which is in mid-stage clinical development for the treatment of advanced primary liver cancer and colorectal cancer and JX-929 which is under investigation for a variety of other solid tumors. The company was founded by John C. Bell and David H. Kirn in 2006 and is headquartered in San Francisco, CA.

MediGene, Inc. develops herpes simplex virus technologies for the treatment of tumors and for gene delivery. The company was founded by Ram Bhatt and Frank Tufaro and is headquartered in San Diego, CA.

Canadian Genetics Diseases Network provides research and development services to the healthcare industry. The company is headquartered in Vancouver, Canada.